Clinical trial NCT00702286: Evaluation of Surface Acoustics Ultrasound Device for the Treatment of Patients With Percutaneous Nephrostomy Catheters
Official title: Phase II Prospective Comparison Randomized Placebo Controlled Double Blind Study to Evaluate the Efficacy of the UroShieldTM Surface Acoustics Ultrasound Device for the Treatment of Patients With Percutaneous Nephrostomy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Urinary Tract Infection
Keywords: Surface acoustic ultrasound
biofilm formation
percoutaneous nephrostomy tube
Patients requiring per coetaneous drainage due to urinary
tract obstruction
To evaluate the efficacy of surface acoustic wave in
reducing pain and improving drainage
Lead sponsor: Assaf-Harofeh Medical Center
Sponsor class: OTHER_GOV
Collaborators: name: Nanovibronix
First posted: 2008-06-20
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All Patients requiring percoutaneous nephrostome drainage for period for more then 4 weeks

Brief summary: Catheter associated urinary tract infection is one of the most common types of catheter acquired infections and adds greatly to patient morbidity, mortality and medical cost. Urinary catheters may readily acquire biofilms when inserted. The longer the catheter remains in place, the greater the tendency of these organisms to develop biofilms and result in urinary tract infections, which are difficult to treathe UroShield System is intended to prevent bacterial biofilm formation by means of the Active NanoShield technology it has developed. A number of scientific concepts and principles shown in prior studies have shown some promising results in the treatment of biofilm based sequele using ultrasound energy. The NanoShield technological basis of the UroShield System has taken these concepts to a level where acoustical waves in the ultrasound range can be created by low cost disposable actuators which actually create a physical coating on all of the surfaces of the catheter thereby interfering with the attachment of bacteria which is the initial step in biofilm formation.

Detailed description: The UroShield™ System is comprised of 2 main components:· The Disposable UroShield Z-Patch - a disposable small lightweight patch that is attached to the PCN catheter, while its opposite side is attached directly to the patient's skin at the site of catheter entry. The patch has twofold function:

1. it receives energy and a signal from the UroShield Driver allowing it to generate the ultrasonic waves;
2. it acts as a fixation device for the PCN catheter.· The UroShield Driver - an external driver unit that is attached to the UroShield patch and contains batteries to power the system and electronics that control the patch unit

Eligibility criteria: Inclusion Criteria:

* Patients requiring percoutaneous nephrostome
* First insertion

Exclusion Criteria:

* Blood coagulation disorders
* Trauma

Primary outcomes:
measure: Reduction in pain and discomfort in patients with PCN catheters, improvement of catheter's patency.
timeFrame: 28 days for one subject overall 1 year
Secondary outcomes:
measure: Renal function improvement
timeFrame: 28 days per pateint overall 1 year
Other outcomes:
Locations:
city: Zerifin
country: Israel
facility: Assaf Harofeh MC
state: Isarel
Study officials:
affiliation: Assaf Harofeh MC
name: Yoram I Siegel, MD
role: PRINCIPAL_INVESTIGATOR
References: